TOVX

Business Context and Reporting Period

Company: Sheffield Pharmaceuticals, Inc. (Note: Request metadata listed "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 1998
Status: Development Stage Enterprise
Operations: The Company is engaged in research, development, and licensing of biomedical technologies, specifically the Multi-Dose Solution Inhaler (MSI) and various HIV/AIDS technologies. It has generated minimal operating revenue and relies on equity and debt offerings to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Crisis: Cash and cash equivalents plummeted from $393,608 at December 31, 1997, to $7,876 at March 31, 1998, a decrease of approximately 98%.
• Expense Reduction: Total operating expenses decreased to $2,264,001 in Q1 1998 from $2,686,313 in Q1 1997. This $422,000 reduction was driven by lower R&D spending ($1.4M decrease) and G&A ($130k decrease), partially offset by a $1.1M expense recognized for a Siemens A.G. license payment due in January 1998.
• Revenue Decline: Interest income dropped to $953 from $18,225 due to reduced cash invested in short-term instruments. No sub-license revenue was recognized in the quarter.
• Debt and Equity Structure: The Company issued 3,093,223 shares of common stock during the quarter via conversion of Series A Preferred Stock and 6% Convertible Debentures.

Outlook, Risks, and Subsequent Events

Management Commentary & Guidance:

• The Company anticipates incurring approximately $2.3 million in additional funding over the next 12 months for clinical research and the final Siemens payment.
• Management believes the ability to continue as a going concern through December 1998 is dependent on obtaining additional financing.
• Committed and anticipated R&D funding after March 31, 1998, is estimated at approximately $16,000,000, primarily for the MSI project.

• Zambon Agreement: On April 15, 1998, the Company entered an option agreement with Zambon Group SpA for a sub-license of the MSI respiratory system. Zambon paid a $650,000 option fee in equity and agreed to fund remaining development costs for respiratory products.
• Series B Offering: On April 15, 1998, the Company issued 1,250 shares of Series B Preferred Stock for $1.25 million. Proceeds were used to pay the overdue DM 2.0 million ($1.1M) Siemens license fee.
• Listing Status: The Company continues to fail to meet certain American Stock Exchange (AMEX) continued listing guidelines.

• Going Concern: Significant doubt exists regarding the Company's ability to meet obligations without additional financing.
• Licensing Default: Failure to make payments to licensors (e.g., Siemens) could result in forfeiture of technology rights.
• Development Risk: No assurance that products will be successfully developed, approved by regulators, or commercialized.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.9 million raised in April 1998 (Zambon fee + Series B) against the $16 million estimated future R&D commitment.
• Siemens Payment: Confirm the status of the DM 2.0 million payment to Siemens A.G. and ensure no further penalties or defaults exist.
• Zambon Definitive Agreement: Monitor the negotiation of the definitive sub-licensing agreement with Zambon, as the $650k fee and funding obligations are contingent on this.
• AMEX Listing: Assess the risk of delisting from the American Stock Exchange and its impact on stock liquidity.
• Preferred Stock Redemption: Review the terms of the Series B Preferred Stock, which must be redeemed upon conclusion of the Zambon sub-license or other financing.